Ospemifene

Ospemifene
Clinical data
Trade names	Osphena, Senshio
Other names	Deaminohydroxytoremifene
AHFS/Drugs.com	Monograph
MedlinePlus	a613039
License data	US DailyMed: Ospemifene;
Routes of; administration	By mouth
Drug class	Selective estrogen receptor modulator
ATC code	G03XC05 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 2-(p-((Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol;
CAS Number	128607-22-7;
PubChem CID	3036505;
DrugBank	DB04938;
ChemSpider	2300501;
UNII	B0P231ILBK;
KEGG	D08958;
ChEBI	CHEBI:73275;
ChEMBL	ChEMBL2105395;
CompTox Dashboard (EPA)	DTXSID101025426 ;
ECHA InfoCard	100.190.672
Chemical and physical data
Formula	C24H23ClO2
Molar mass	378.90 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1;
	InChI InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-; Key:LUMKNAVTFCDUIE-VHXPQNKSSA-N;

Ospemifene (brand names Osphena and Senshio produced by Shionogi) is an oral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by vulvovaginal atrophy.

The medication was approved by the US Food and Drug Administration in February 2013, and by the European Medicines Agency for marketing in the European Union in January 2015.